よむ、つかう、まなぶ。
参考資料15 COVID-19 vaccine safety update; Primary series in young children and booster doses in older children and adults, ACIP September 1, 2022 (10 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000208910_00052.html |
| 出典情報 | 第85回厚生科学審議会予防接種・ワクチン分科会副反応検討部会、令和４年度第14回薬事・食品衛生審議会薬事分科会医薬品等安全対策部会安全対策調査会（合同開催）（10／7）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
U.S. reports to VAERS among children after primary series Pfizer-BioNTech (ages 6
months–4 years) or Moderna (ages 6 months–5 years) vaccination* (as of August 21, 2022)
Doses
Manufacturer admin†
Total
reports
Median
age
Male‡
n (%)
Female‡
n (%)
Nonserious
n (%)
Serious§
n (%)
Myocarditis
reports (n)
PfizerBioNTech
890,378
496
3 years
249 (50)
245 (49)
486 (98)
10 (2)
0
Moderna
664,484
521
2 years
272 (52)
240 (46)
512 (98)
9 (2)
0
Total
1,554,862
1,017
3 years
521 (51)
485 (48)
998 (98)
19 (2)
0
* Among children ages 6 months–4 years after Pfizer-BioNTech, and among children ages 6 months–5 years after Moderna, vaccinated during June 18–August 21,
2022; reports received and processed as of August 23, 2022
† Dose 1 and dose 2 administered among children described in previous footnote during June 16–August 18, 2022.
‡ 2 reports after Pfizer-BioNTech and 9 reports after Moderna did not have sex reported
§ Based on the Code of Federal Regulations if one of the following is reported: death, life-threatening illness, hospitalization or prolongation of hospitalization,
permanent disability, congenital anomaly or birth defect
10
months–4 years) or Moderna (ages 6 months–5 years) vaccination* (as of August 21, 2022)
Doses
Manufacturer admin†
Total
reports
Median
age
Male‡
n (%)
Female‡
n (%)
Nonserious
n (%)
Serious§
n (%)
Myocarditis
reports (n)
PfizerBioNTech
890,378
496
3 years
249 (50)
245 (49)
486 (98)
10 (2)
0
Moderna
664,484
521
2 years
272 (52)
240 (46)
512 (98)
9 (2)
0
Total
1,554,862
1,017
3 years
521 (51)
485 (48)
998 (98)
19 (2)
0
* Among children ages 6 months–4 years after Pfizer-BioNTech, and among children ages 6 months–5 years after Moderna, vaccinated during June 18–August 21,
2022; reports received and processed as of August 23, 2022
† Dose 1 and dose 2 administered among children described in previous footnote during June 16–August 18, 2022.
‡ 2 reports after Pfizer-BioNTech and 9 reports after Moderna did not have sex reported
§ Based on the Code of Federal Regulations if one of the following is reported: death, life-threatening illness, hospitalization or prolongation of hospitalization,
permanent disability, congenital anomaly or birth defect
10